secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2024-09-20T23:59:59+00:00
Accession:  0001193125-24-222429
Event type: litigation
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo faces two shareholder lawsuits over OnKure merger proxy; provides supplemental disclosures
--------------------------------------------------------------------------------

- Two complaints filed in NY Supreme Court allege misrepresentations/omissions in proxy regarding financial projections and advisor conflicts.
- Reneo denies allegations but voluntarily supplements proxy with details on Leerink's $40k prior compensation and 5% aggregate placement agent fee.
- Supplemental disclosures include unadjusted OnKure forecasts showing projected net sales up to $3B by 2042 and DCF equity value range of $180M-$290M.
- Reneo confirms no internal liquidation analysis was prepared; board relied on OnKure forecasts and $15M enterprise value ascribed to Reneo.
- Merger and concurrent PIPE expected to close; company intends to vigorously defend against litigation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000119312524222429/0001193125-24-222429-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000119312524222429/d844965d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-222429

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer